Shots:
- Formycon and licensing partner Klinge Biopharma have reported the EU launch of FYB203, a biosimilar version of Eylea 2mg (aflibercept)
- FYB203 is now available in the EU as a PFS under the brand names Ahzantive and Baiama. The launch began on May 15, 2026, in key markets including Germany, France, and Italy, with further expansion across Central and Eastern Europe planned in the coming months
- In March 2026, Formycon signed a settlement and licensing agreement with Regeneron and Bayer, enabling the European launch on May 15, 2026. Earlier, in October 2025, Formycon secured a U.S. launch timeline for Q4’26, with the possibility of an earlier entry under certain conditions
Ref: Formycon | Image: Klinge Biopharma and Formycon | Press Release
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
